Obesity in the spotlight (part II)

ADA conference updates on oral obesity treatments

Bohdan (Bo) Khomtchouk, Ph.D.

Jun 26, 2023

∙ Paid

Read part I here:

Obesity in the spotlight

Bohdan (Bo) Khomtchouk, Ph.D.

June 6, 2023

Last month, we reported on various new oral obesity treatments and provided an assessment of the competitive landscape surrounding the GLP-1 market. Today, we will cover what drug classes are shaping up to be the foundation of obesity, what drugs have the most promising weight loss data, and how smaller innovators can challenge the big pharma incumbent…

Read full story

Today, we will cover new obesity data from big pharma competitors presented at the American Diabetes Association (ADA) conference this past weekend. The trend is moving towards developing oral GLP-1 drugs, different from the current standard administration of subcutaneous injections (Novo’s Ozempic & incoming Mounjaro from Eli Lilly).

I…

Boutique Biotech

Obesity in the spotlight (part II)

ADA conference updates on oral obesity treatments

Obesity in the spotlight

This post is for paid subscribers